CMET-40. THE DEVELOPMENT OF BRAIN METASTASIS IN THE PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AND MELANOMA TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A RETROSPECTIVE ANALYSIS

摘要

BACKGROUNDSurvival benefit with immune checkpoints inhibitors in patients with metastatic NSCLC and Melanoma has been demonstrated. However, the published results do not describe the incidence of brain metastasis as a site of recurrence in these patients. We sought to determine the incidence of central nervous system (CNS) relapse/progression relative to systemic response in patients with NSCLC or Melanoma treated with a PD-1 inhibitor.